Granite Bio makes $100m debut, and other bio financings

Granite Bio makes $100m debut, and other bio financings

Our round-up of recent biotech financings includes rounds for Granite Bio, Biolinq, Etiome, Grove Biopharma, and Synthetic Design Lab.

Granite Bio Debuts With $100 Million of Capital

BASEL, Switzerland & SAN FRANCISCO -- Granite Bio AG, a clinical-stage immunology company, has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund, and a $70 million Series B led by Forbion and Sanofi Ventures.

Versant startup Granite debuts with $100M and two immune drugs

The young biotech, sprung out of a Versant incubator in Switzerland, has a pair of antibody drugs it claims to have the potential to treat multiple autoimmune conditions.

Granite Bio secures $100m in funding for new antibodies

Granite Bio has secured $100m in funding for its new antibody treatments that target several autoimmune diseases.

Versant's Granite Bio unveils with $100M for new autoimmune disease antibodies

Granite Bio is ready to rock ‘n’ roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting several autoimmune diseases. The funding consists of a $30 million series A led by founding investors Versant Ventures and Novartis Venture Fund, plus a $70 million series B round led by Forbion and Sanofi Ventures, […] The post Versant’s Granite Bio unveils with $100M for new autoimmune disease antibodies appeared first on O…

Granite Bio Raises $100M in Funding

Granite Bio, a Basel, Switzerland-based clinical-stage immunology company, raised $100M in funding. The round consisted of a $30M Series A led by Versant Ventures and Novartis Venture Fund, and a $70M Series B led by Forbion and Sanofi Ventures. The company intends to use the funds to expand operations and its R&D efforts. Granite Bio […] The post Granite Bio Raises $100M in Funding appeared first on FinSMEs.